{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T23:59:03Z","timestamp":1785110343799,"version":"3.55.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007553","name":"Aidsfonds","doi-asserted-by":"publisher","award":["P-54601"],"award-info":[{"award-number":["P-54601"]}],"id":[{"id":"10.13039\/100007553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Successful implementation of oral pre-exposure prophylaxis (PrEP) requires retention in PrEP care among those with an increased likelihood of HIV. This study aimed to estimate the proportion of retention on PrEP and extent to which variability in PrEP retention is associated with population-, program-, and study-specific characteristics among men who have sex with men (MSM) and transgender persons (TGP). We performed a systematic review and meta-analysis examining PrEP studies and conference abstracts retrieved from the PubMed and Ovid online databases, capturing demonstration projects or observational studies published from January 1, 2010 to March 24, 2021. We included 84 studies (totaling 90 study \u201ccohorts\u201d analyzed) that reported on the retention of oral PrEP for HIV and included predominantly MSM and TGP. The proportion of retained participants was obtained from each study and used to estimate the cumulative probability of being retained on PrEP and the loss of PrEP retention rate over time via a random-effects meta-analysis survival model. We examined sources of heterogeneity by including study-level covariates in this model. The pooled cumulative probability of PrEP retention was 77.0%, 64.7%, 48.5%, and 24.1% at 6, 12, 24, and 60 months, respectively. Loss of PrEP retention rates were significantly (p\u2009&lt;\u20090.05) lower in studies from Europe, Australia and multiple regions (vs. North America), and with \u22653-monthly follow-up (vs.\u2009&lt;\u20093). Rates were significantly higher in studies from Africa (vs. North America), with lower median age, higher proportions of non-MSM\/TGP participants, higher proportions of participants with unspecified (vs. mixed) ethnicity, with unspecified (vs. daily) PrEP regimen, free-of-charge (vs. unspecified) STI testing, whose data were from conference abstracts (vs. peer-reviewed papers), and that were more recent. In conclusion, oral PrEP retention decreased over time and differed across population-, program-, and study-specific characteristics. The heterogeneity across studies highlights PrEP implementation challenges and the need for tailored retention strategies.<\/jats:p>","DOI":"10.1371\/journal.pone.0333494","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:29:00Z","timestamp":1760722140000},"page":"e0333494","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral pre-exposure prophylaxis retention among men who have sex with men and transgender persons: Systematic review and meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-9364","authenticated-orcid":true,"given":"Feline","family":"de la Court","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O. T.","family":"ten Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Hoornenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-7002","authenticated-orcid":true,"given":"Maarten F.","family":"Schim van der Loeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Coyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-8928","authenticated-orcid":true,"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"22","key":"pone.0333494.ref001","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1001\/jama.2019.2591","article-title":"Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"321","author":"R Chou","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"pone.0333494.ref002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"JE Haberer","year":"2015","journal-title":"AIDS"},{"issue":"4","key":"pone.0333494.ref003","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.chom.2020.03.020","article-title":"PrEP for HIV prevention: evidence, global scale-up, and emerging options","volume":"27","author":"C Celum","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"12","key":"pone.0333494.ref004","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/QAD.0000000000002598","article-title":"Oral preexposure prophylaxis continuation, measurement and reporting","volume":"34","author":"K Stankevitz","year":"2020","journal-title":"AIDS"},{"issue":"8","key":"pone.0333494.ref005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.22692","article-title":"Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System","volume":"4","author":"JC Hojilla","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"pone.0333494.ref006","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25472","article-title":"Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States","volume":"23","author":"MA Spinelli","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0333494.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"J Zhang","year":"2022","journal-title":"Lancet HIV"},{"key":"pone.0333494.ref008","doi-asserted-by":"crossref","first-page":"100889","DOI":"10.1016\/j.pmedr.2019.100889","article-title":"Demographic characteristics associated with the use of HIV pre-exposure prophylaxis (PrEP) in an urban, community health center","volume":"15","author":"M Caponi","year":"2019","journal-title":"Prev Med Rep"},{"issue":"1","key":"pone.0333494.ref009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/COH.0000000000000206","article-title":"The role of healthcare providers in the roll out of preexposure prophylaxis","volume":"11","author":"DS Krakower","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"pone.0333494.ref010","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s10461-019-02577-7","article-title":"Expanding Knowledge About Implementation of Pre-exposure Prophylaxis (PrEP): A Methodological Review","volume":"23","author":"RM Pinto","year":"2019","journal-title":"AIDS Behav"},{"issue":"11","key":"pone.0333494.ref011","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1007\/s10461-018-2045-1","article-title":"Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men","volume":"22","author":"THF Whitfield","year":"2018","journal-title":"AIDS Behav"},{"issue":"10","key":"pone.0333494.ref012","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"M Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0333494.ref013","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"pone.0333494.ref014","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","article-title":"Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature","volume":"21","author":"FM Koechlin","year":"2017","journal-title":"AIDS Behav"},{"issue":"14","key":"pone.0333494.ref015","article-title":"Preexposure chemoprophylaxis for HIV prevention","volume":"364","author":"K Underhill","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0333494.ref016","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1002\/sim.3311","article-title":"Meta-analysis of summary survival curve data","volume":"27","author":"LR Arends","year":"2008","journal-title":"Stat Med"},{"issue":"3","key":"pone.0333494.ref017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model","volume":"30","author":"W Viechtbauer","year":"2005","journal-title":"J Educ Behav Stat"},{"issue":"3","key":"pone.0333494.ref018","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jrsm.1053","article-title":"GOSH - a graphical display of study heterogeneity","volume":"3","author":"I Olkin","year":"2012","journal-title":"Res Synth Methods"},{"issue":"2","key":"pone.0333494.ref019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"W Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"issue":"7109","key":"pone.0333494.ref020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"issue":"10","key":"pone.0333494.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(20)30203-4","article-title":"Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies","volume":"7","author":"SE Rutstein","year":"2020","journal-title":"Lancet HIV"},{"issue":"4","key":"pone.0333494.ref022","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000002054","article-title":"Predictors of Disengagement in Care for Individuals Receiving Pre-exposure Prophylaxis (PrEP)","volume":"81","author":"J Zucker","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pone.0333494.ref023","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s12325-020-01295-0","article-title":"Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review","volume":"37","author":"KH Mayer","year":"2020","journal-title":"Adv Ther"},{"issue":"7","key":"pone.0333494.ref024","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s10461-018-2296-x","article-title":"PrEP in the Real World: Predictors of 6-Month Retention in a Diverse Urban Cohort","volume":"23","author":"AJ Lankowski","year":"2019","journal-title":"AIDS Behav"},{"issue":"6","key":"pone.0333494.ref025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/QAD.0000000000001006","article-title":"HIV testing, risk perception, and behaviour in the British population","volume":"30","author":"S Clifton","year":"2016","journal-title":"AIDS"},{"key":"pone.0333494.ref026","doi-asserted-by":"crossref","first-page":"100650","DOI":"10.1016\/j.eclinm.2020.100650","article-title":"Understanding pre-exposure prophylaxis (PrEP) regimen use: Switching and discontinuing daily and event-driven PrEP among men who have sex with men","author":"L Coyer","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10","key":"pone.0333494.ref027","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy368","article-title":"Trajectories and predictors of longitudinal preexposure prophylaxis adherence among men who have sex with men","volume":"218","author":"EC Pasipanodya","year":"2018","journal-title":"J Infect Dis"},{"issue":"10","key":"pone.0333494.ref028","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1007\/s10461-019-02502-y","article-title":"Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color","volume":"23","author":"S Wood","year":"2019","journal-title":"AIDS Behav"},{"issue":"3","key":"pone.0333494.ref029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/sextrans-2017-053217","article-title":"Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV","volume":"94","author":"K Yun","year":"2018","journal-title":"Sex Transm Infect"},{"issue":"11","key":"pone.0333494.ref030","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1007\/s10461-018-2125-2","article-title":"High Rate of Discontinuation May Diminish PrEP Coverage Among Young Men Who Have Sex with Men","volume":"22","author":"E Morgan","year":"2018","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0333494.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000003635","article-title":"The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis","volume":"99","author":"H Wang","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pone.0333494.ref032","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12913-020-05568-w","article-title":"The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review","volume":"20","author":"J Vanhamel","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"pone.0333494.ref033","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/sextrans-2016-052699","article-title":"Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool","volume":"93","author":"T Reyniers","year":"2017","journal-title":"Sex Transm Infect"},{"key":"pone.0333494.ref034","doi-asserted-by":"crossref","first-page":"21119","DOI":"10.7448\/IAS.19.7.21119","article-title":"PrEP implementation in the Asia-Pacific region: opportunities, implementation and barriers","volume":"19","author":"I Zablotska","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"pone.0333494.ref035","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41591-020-0872-x","article-title":"PrEP rollout in Africa: status and opportunity","volume":"26","author":"EM Irungu","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"pone.0333494.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(21)00005-9","article-title":"HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study","volume":"8","author":"C Laurent","year":"2021","journal-title":"Lancet HIV"},{"issue":"7","key":"pone.0333494.ref037","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/hiv.13237","article-title":"Stopping and restarting PrEP and loss to follow-up among PrEP-taking men who have sex with men and transgender women at risk of HIV-1 participating in a prospective cohort study in Kenya","volume":"23","author":"E Wahome","year":"2022","journal-title":"HIV Med"},{"issue":"9","key":"pone.0333494.ref038","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s10461-020-02807-3","article-title":"Understanding PrEP Persistence: Provider and Patient Perspectives","volume":"24","author":"ND Laborde","year":"2020","journal-title":"AIDS Behav"},{"issue":"2","key":"pone.0333494.ref039","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/tbm\/ibz191","article-title":"Insurance- and medical provider-related barriers and facilitators to staying on PrEP: results from a qualitative study","volume":"11","author":"AB D\u2019Angelo","year":"2021","journal-title":"Transl Behav Med"},{"issue":"6","key":"pone.0333494.ref040","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(22)00106-2","article-title":"Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study","volume":"7","author":"H Jourdain","year":"2022","journal-title":"Lancet Public Health"},{"issue":"14","key":"pone.0333494.ref041","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1097\/QAD.0000000000002347","article-title":"Racial\/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics","volume":"33","author":"HM Scott","year":"2019","journal-title":"AIDS"},{"issue":"2","key":"pone.0333494.ref042","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"A Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"pone.0333494.ref043","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women","volume":"385","author":"RJ Landovitz","year":"2021","journal-title":"New Engl J Med"},{"key":"pone.0333494.ref044","unstructured":"World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. 2022."},{"issue":"6","key":"pone.0333494.ref045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/hiv.13451","article-title":"Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?","volume":"24","author":"G Liegeon","year":"2023","journal-title":"HIV Med"},{"issue":"6","key":"pone.0333494.ref046","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00079-6","article-title":"The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities","volume":"10","author":"JE Haberer","year":"2023","journal-title":"Lancet HIV"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:29:11Z","timestamp":1760722151000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333494"}},"subtitle":[],"editor":[{"given":"Steve","family":"Zimmerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0333494","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}